VTGN · Vistagen Therapeutics, Inc.
$0.24
+0.01 (+4.64%)
At close · Jul 29
Going-concern doubt
— flagged Jun 15, 2026
Substantial doubt about the company's ability to continue as a going concern.
“As of June 15, 2026, the issuance date of the consolidated financial statements as of and for the year ended March 31, 2026, there is uncertainty about whether the Company’s combined cash, cash equivalents, and marketable securities will be sufficient to fund operations beyond twelve months from the issuance date of these consolidated financial statements and therefore the Company concluded that substantial doubt existed about the Company’s ability to continue as a going concern.”View the 10-K filed Jun 15, 2026
Market Cap
$9.55M
Shares
41.03M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$1.27M
+161.1%
FY2026
Net Income
-$69.69M
-35.5%
FY2026
Operating Margin
-5683.69%
+5833.4pp
FY2026
Diluted EPS
-$1.83
-9.6%
FY2026
Operating Cash Flow
-$66.44M
-57.8%
FY2026
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2012 | FY2013 | FY2011 | FY2010 | FY2009 | FY2008 | FY2007 | FY2006 | FY2005 | FY2004 | FY2003 | FY2002 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | $1.27M | $486K | $1.06M | -$227K | $1.11M | $1.09M | $0 | — | $0 | $1.25M | $0 | — | $16.37M | $16.37M | $200.4K | $16.17M | — | — | — | — | — | — | — | — | — | |
| $1.84M | — | — | — | $26.2K | $19.9K | $1600 | $30.1K | -$8000 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| — | $54.97M | $39.38M | $20.02M | $44.38M | $35.41M | $11.93M | $13.37M | $17.1M | $7.76M | $5.2M | $3.93M | $2.43M | $2.48M | $29.56M | $3.43M | $26.12M | — | — | — | — | — | — | — | — | — | |
| — | $18.42M | $17.08M | $14.06M | $14.66M | $13.48M | $7.1M | $7.43M | $7.46M | $6.44M | $6.29M | $13.92M | $4.34M | $2.55M | $30.68M | $3.56M | $27.12M | — | — | — | — | — | — | — | — | — | |
| — | $199K | $150K | $127K | $130K | $153.5K | $117.6K | $103.1K | $91.2K | $80.7K | $54.9K | $53.5K | $59.1K | $54.6K | $777.5K | $33.8K | $743.7K | — | — | — | — | — | — | — | — | — | |
| — | $73.4M | $56.46M | $34.09M | $59.04M | $48.89M | $19.02M | $20.8M | $24.56M | $14.2M | $11.5M | $17.85M | $6.78M | $5.03M | $67.76M | $6.99M | $60.77M | — | — | — | — | — | — | — | — | — | |
| — | -$72.13M | -$55.97M | -$33.02M | -$59.27M | -$47.78M | -$17.93M | -$20.8M | -$24.56M | -$14.2M | -$10.25M | -$17.85M | -$6.78M | -$5.03M | -$51.39M | -$6.79M | -$44.6M | — | — | — | — | — | — | — | — | — | |
| — | -5683.69% | -11517.08% | -3103.48% | — | -4308.29% | -1646.06% | — | — | — | -819.88% | — | — | -30.72% | -313.92% | -3389.77% | -275.8% | — | — | — | — | — | — | — | — | — | |
| — | -$71.93M | -$55.82M | -$32.89M | -$59.14M | -$47.63M | -$17.82M | -$20.7M | -$24.47M | -$14.12M | -$10.19M | -$17.8M | -$6.72M | -$4.97M | -$50.61M | -$6.76M | -$43.85M | — | — | — | — | — | — | — | — | — | |
| — | — | — | — | — | — | — | — | $8000 | $8900 | $4600 | $770.8K | $4.55M | $1.5M | -$10.36M | -$920.7K | $9.44M | — | — | — | — | — | — | — | — | — | |
| — | — | — | — | — | $0 | $600 | — | — | — | $0 | -$2300 | -$135K | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| — | -$69.68M | -$51.41M | -$29.36M | -$59.24M | -$47.76M | -$17.93M | -$20.77M | -$24.59M | -$14.34M | -$10.25M | -$47.22M | -$13.88M | -$2.97M | -$67.65M | -$12.88M | -$54.77M | — | — | — | — | — | — | — | — | — | |
| — | $7000 | $7000 | $4000 | $6000 | $3400 | $2600 | $2600 | $2600 | $2400 | $2400 | $2300 | $2400 | $2700 | $20.5K | $3700 | $16.8K | — | — | — | — | — | — | — | — | — | |
| — | -$69.69M | -$51.42M | -$29.36M | -$59.25M | -$47.76M | -$17.93M | -$20.77M | -$24.59M | -$14.35M | -$10.26M | -$47.22M | -$13.89M | -$2.97M | -$67.67M | -$12.89M | -$54.78M | -$4.12M | -$4.7M | -$5.45M | -$2M | -$1.77M | -$1.08M | -$8.76M | -$502.6K | -$2.11M | |
| — | -5491.33% | -10579.84% | -2759.59% | — | -4306.8% | -1646.09% | — | — | — | -820.44% | — | — | -18.13% | -413.37% | -6430.49% | -338.8% | — | — | — | — | — | — | — | — | — | |
| — | — | — | — | -$59.25M | -$48.71M | -$42.32M | -$22.04M | -$25.73M | -$15.58M | -$11.62M | -$51.42M | -$13.89M | -$2.97M | — | $185.7K | — | — | — | — | — | — | — | — | — | — | |
| — | -$69.69M | -$51.41M | -$29.36M | -$59.25M | — | — | — | — | — | — | — | — | -$70.64M | — | -$12.89M | — | — | — | — | — | — | — | — | — | — | |
| USD/shares | — | -$1.83 | -$1.67 | -$1.52 | -$8.51 | -$7.38 | -$14.70 | — | — | — | — | -$872.40 | -$315.90 | -$81.00 | — | $0.30 | — | — | — | — | — | — | — | — | — | — |
| USD/shares | — | -$1.83 | -$1.67 | -$1.52 | -$8.51 | — | — | — | — | — | — | -$872.40 | -$318.30 | -$114.30 | -$24.90 | -$0.60 | -$54.30 | — | — | — | — | — | — | — | — | — |
| shares | — | 38.07M | 30.88M | 19.35M | 6.96M | 6.6M | 2.87M | 1.46M | 952.08K | 463K | 251.05K | 58.93K | 43.96K | 36.62K | — | 694.66K | — | — | — | — | — | — | — | — | — | — |
| shares | — | 38.07M | 30.88M | 19.35M | 6.96M | — | 2.87M | 1.46M | 952.08K | 463K | 251.05K | 58.93K | 43.96K | 36.64K | 491.22K | 694.66K | 174.7K | — | — | — | — | — | — | — | — | — |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Showing the latest 26 of 27 periods — chart a line item for full history.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
EV/EBIT
—
P/E (TTM)
—
Peer median 0.04×
Peer medians compare against the 193 similar-size Biotechnology companies (of 522 listed).
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Product & Service (USD)
| Component | FY2023 | FY2022 |
|---|---|---|
| License | -$227,000 | $1,109,000 |